Loss of peroxisome proliferator-activated receptor gamma (PPARγ) function in vascular endothelium 23 enhances atherosclerosis and nuclear factor-kappa-B (NF-κB) target gene expression in high fat diet 24 fed apolipoprotein-E-deficient mice. The mechanisms by which endothelial PPARγ regulates 25 inflammatory responses and protects against atherosclerosis remain unclear. To assess functional 26 interactions between PPARγ and inflammation, we employed a model of interleukin-1β 27 (IL-1β)-induced aortic dysfunction in transgenic mice with endothelial-specific overexpression of 28 either wildtype (E-WT) or dominant negative PPARγ (E-V290M).
age) carrying wide-type (E-WT) or dominant negative (E-V290M) form of human PPARγ under the 119 control of the endothelium-specific vascular cadherin (Ve-cad) promoter as described previously (5). 120
Age-matched non-transgenic (NT) littermates were used as controls. Care of these mice met the of proteins (15-35 µg) were separated by SDS-PAGE (8-12 %) and transferred to a nitrocellulose 131 membrane (GE healthcare). After blocking with 5% skim milk, membranes were incubated with 132 primary antibodies at 4 o C overnight and then visualized using horseradish peroxidase-conjugatedutilized as a loading control (ab16039, Abcam). 137
138
Bioluminescence imaging: Luciferase assay was performed using NF-κB-LUC mice. After 139 treatment of isolated aorta with IL-1β (0-500 pg/ml) for 24 hr, sample was washed using ice-cold 140
Dulbecco's phosphate-buffered saline (dPBS) and incubated with dPBS including 1.5 mg/ml 141
D-luciferin (Gold Biotechnology) (42). Bioluminescence imaging was performed on a Xenogen 142
IVIS-200 System. Luminescence was quantitated where peak of the luminescent signal occurred. 143
144
Vascular function: Aortic function was assessed using a wire myograph preparation. Thoracic aorta 145 was dissected free of perivascular fat and cut into 4 segments. After three washes with sterile 146 phosphate buffered saline, aorta rings were placed in Dulbecco's Modified Eagle Medium/Nutrient 147 Mixture F-12 (DMEM/F-12) supplemented with 1% penicillin-streptomycin in the absence (control) or 148 presence of IL-1β (0.1-500 pg/ml, 30 min-24 hr). Aortic rings were pre-treated with indicated agents 149 (rosiglitazone, NF-κB p65 inhibitor, tempol, or vehicle) for 1 hr at 37 o C in an atmosphere of 95% air 150 and 5% CO 2 and then incubated in the absence (control) or presence of IL-1β (0.1-500 pg/ml, 24 hr). 151 Aortic rings were then equilibrated for 45 min under a resting tension of 0.5 grams, and(PGF2α, 3-10 μM). 156
157
Real-time RT-PCR: Total RNA was extracted from thoracic aorta using RNeasy spin columns 158 (RNeasy Mini Kit, QIAGEN). cDNA was synthesized from 500-800 ng of total RNA by RT-PCR 159 using Superscript III (Invitrogen), RNaseOUT (Invitrogen), and oligo(dT) primers. Q-PCR reactions 160 were performed in duplicate using Taqman Fast Advanced Master Mix (Applied Biosystems), 161 TaqMan Gene Expression Assays (Applied Biosystems) and 10 ng of cDNA in a total volume of 10 l. 162 For Taqman assays, the Applied Biosystems StepOnePlus System was used (4352932-0905028 for 163 GAPDH). In some experiments, Q-PCR reactions were performed using Fast SYBR Green Master 164 Mix (Applied Biosystems), target gene primers, and 10 ng of cDNA in a total volume of 10 µl. Statistical analysis: Experiments were performed in similar numbers between male and female mice. 184 We observed that there was no difference between the sex of mice, therefore, data were pooled from 185 both. Results are expressed as mean±SEM. Statistical evaluation of the data was performed 186 using GraphPad Prism. Where appropriate, a paired or unpaired Student's t-test was used toincreased p65 phosphorylation without affecting total expression of p65, and reduced the levels of 195
Iκ-Bα ( Figure 1A ). This indicates that IL-1β activated NF-κB signaling in the whole aorta. IL-1β 196 treatment of aorta isolated from NF-κB-LUC mice consistently caused a dose-dependent increase in 197 NF-κB transcriptional activity ( Figure 1B and C) . ablation of ACh-induced vasodilation in NT aorta, and this maximal level of dysfunction could not be 231 worsened in aorta from E-V290M mice (n=3, maximum relaxation by ACh; NT, -5.17±9.96%; 232 E-V290M, 3.90±6.25%). There was no difference in SNP-induced relaxation (Figure 4) and 233 KCl-induced contraction (data not shown) between NT and E-V290M. These data support the 234 hypothesis that endothelial PPARγ functions to protect against IL-1β-induced endothelial dysfunction 235 in the aorta. 236
237

NF-κB activity does not affect EC dysfunction by IL-1β 238
We showed that IL-1β induces NF-κB activity in aorta (Figure 1 ). In order to determine if IL-1β 239 induced endothelial dysfunction requires activation of NF-κB, we utilized an NF-κB p65 inhibitory 240 peptide at a concentration which blunted IL-1β (20 pg/ml)-induced luciferase activity in aorta from 241 NF-κB-LUC mice ( Figure 5A ). However, the NF-κB inhibitor did not affect endothelial dysfunction 242 induced by IL-1β at any dose in aorta from NT mice ( Figure 5B and C). The inhibitor modestly 243 improved endothelial-independent relaxation in aorta treated with low-dose IL-1β ( Figure 5B) , 244 suggesting that NF-κB activity may contribute to IL-1β-induced dysfunction in SMC. Importantly, 245 IL-1β-induced impairment of vasodilation to ACh was also not altered by the NF-κB inhibitor in aorta 246 from E-WT mice (n=6, data not shown), suggesting that the protective actions of endothelial PPARγare not dependent on altering NF-κB activity.
Consistent with this, endothelial-specific 248 over-expression of WT PPARγ in E-WT mice did not blunt the induction of the NF-κB target genes 249 iNOS, MCP1, or ICAM1 in IL-1β-treated aorta ( Figure 6 ). Similarly, there was no effect on 250 IL-1β-induced iNOS protein levels in aorta from E-WT mice (NT+vehicle: 1.00±0.90; NT+IL-1β: 251 4.02±0.67; E-WT+vehicle: 1.08±0.69; E-WT+IL-1β: 3.57±0.33, n=3). 252
253
IL-1β induces vascular dysfunction via increasing ROS 254
Oxidative stress has been implicated in endothelial dysfunction and cardiovascular diseases. We 255 next used a ROS scavenger to test if increased ROS plays a role in IL-1β-mediated endothelial 256 dysfunction. Tempol significantly improved ACh-mediated dilation of IL-1β-treated aorta from NT 257 mice ( Figure 7A ), but had a blunted effect on aorta from E-WT mice ( Figure 7B ) when both were 258 treated with the same dose of IL-1β (500 ng/ml). Although the maximal relaxation in response to 259 tempol was similar in both groups (maximum relaxation by ACh; NT tempol+IL-1β: 47.98±4.57%; 260 E-WT tempol+IL-1β: 51.59±5.55%), the effect size of tempol was greater on NT aorta compared to 261 E-WT (difference in maximum relaxation by ACh between tempol+IL-1β and IL-1β alone, NT: 262 54.39±4.03%; E-WT, 19.86±7.75%, p<0.05). Analysis of area under the curve also showed that the 263 effect of tempol was greater on NT (IL-1β: 1083±24 vs tempol+IL-1β: 810±75) aorta compared to 264 E-WT (IL-1β: 904±34 vs tempol+IL-1β: 806±29). This suggests that there is at least some 265 redundancy in the protection mediated by tempol and endothelial PPARγ. Consistent with this,tempol also improved IL-1β-induced impairment in E-V290M aorta ( Figure 7D ), but with larger effect 267 compared to NT ( Figure 7C ) when tested at the same low dose of IL-1β (20 pg/ml, difference in 268 maximum relaxation by ACh between tempol+IL-1β and IL-1β alone, NT: 12.79±5.43%; E-V290M, 269 25.65±12.42%). Similarly, analysis of area under the curve showed that tempol caused a greater 270 improvement in the IL-1β-induced impairment in E-V290M aorta (IL-1β: 999±42 vs. tempol+IL-1β: 271 812±33) compared to NT (IL-1β: 835±35 vs. tempol+IL-1β: 765±38). Tempol had no effect on the 272 response to SNP in any groups (Figure 7) . 
Overexpressing endothelial PPARγ preserved activity of eNOS 294
In aorta, ACh-induced relaxation mainly depends on eNOS activity, which is partly determined by the 295 prevalence of phospho-serine 1177 within the total eNOS population (11). In aorta from NT mice, 296 IL-1β (500 pg/ml) caused an increase in eNOS expression, but with a concomitant decrease in the 297 phospho-eNOS/eNOS ratio, consistent with a marked EC dysfunction (Figure 10) . Interestingly, the 298 ratio of phospho-eNOS/eNOS was preserved in IL-1β-treated aorta from E-WT mice. Conversely, 299 loss of PPARγ function in the endothelium (E-V290M) resulted in a sharp reduction in the ratio ofcontrast, we previously showed that interference with PPARγ function in SMC or EC exacerbated 308 aortic atherosclerosis with increased NF-κB target gene expression in ApoE-deficient mice (35). 309
Because IL-1β is an NF-κB activator and contributes to the development of atherosclerosis (29) reduce NF-κB activity (46), although the mechanism of this effect was not determined. However, 320 direct effects of PPARγ on NF-κB have been documented in other cell types. In macrophages, 321 inflammatory gene expression is inhibited through a "transrepression" mechanism in which PPARγprotection from IL-1β-induced EC dysfunction. Specifically, neither expression of p65 protein nor its 327 activating phosphorylation (Ser536) was altered by overexpression of WT PPARγ in IL-1β-treated 328 aorta (n=3, data not shown). We also did not detect any changes in NF-κB-mediated gene 329 expression associated with PPARγ activity in aorta. Thus, we were not able to demonstrate that 330 reported mechanisms of PPARγ-mediated interference with NF-κB are operative in vascular ECs. 331 We also did not find evidence that NF-κB activity contributed to EC dysfunction induced by 332 inflammatory cytokines, since this dysfunction was not reduced by an NF-κB p65 inhibitor. 333 Similarly, suppression of vascular endothelial-specific NF-κB did not decrease blood 334 pressure in a complex model of hypertension involving angiotensin-II infusion, high salt and 335 treatment with L-NAME (16). Conversely, activation of NF-κB was reported to protect against 336 endothelial apoptosis (25) through its target gene, A1 (41), or the immediate early response gene X-1 337 (39).
These evidences indicate that NF-κB activity in vascular EC might not impair 338 endothelial-dependent vasodilation directly, and that other pathways may be responsible forand hypertension (2, 22). Moreover, cardiovascular risk factors including atherosclerosis (19), 346 diabetes (17) and hypertension (44), are associated with an increase in eNOS expression rather 347 than a decrease (27). Expression of eNOS is also increased in the presence of superoxide, through 348 H 2 O 2 -mediated transcriptional and post-transcriptional mechanisms (13). Consistent with these 349 reports, our present study showed that an inflammatory cytokine robustly decreased the 350 phospho-eNOS ser1177 /eNOS ratio. These findings are consistent with a marked endothelial 351 dysfunction caused by an IL-1β-induced increased in ROS. Importantly, the non-inflammatory level 352 of eNOS activity was preserved in aorta from E-WT mice. 353 We provided several lines of evidences to indicate that endothelial PPARγ diminished the 354 effects of oxidative stress induced by IL-1β. First, a ROS scavenger, tempol significantly lessened 355 the impairment of ACh relaxation induced by IL-1β in aorta from NT mice. Second, the magnitude 356 of this tempol-mediated protection was markedly blunted in aorta from E-WT mice compared with 357 aorta from NT mice. Third, endothelial PPARγ prevented the NAPDH oxidase-dependent increase in IL-1β-treated aorta, suggesting that PPARγ reduces ROS production through some other 362 mechanism. The ability of EC PPARγ to preserve a non-inflammatory profile of eNOS activity 363 suggests possible protection against the uncoupling of eNOS activity associated with IL-1β-induced 364 ROS. However, we also showed that ROS accumulation and decreased eNOS activity in aorta 365 from E-V290M did not cause endothelial dysfunction in the absence of IL-1β. These data indicate 366 that increased ROS and reduced eNOS activity by themselves don't cause vascular dysfunction, but 367 increase susceptibility to IL-1β-induced dysfunction. Moreover, that tempol nor expression of WT 368
PPARγ did not fully correct endothelial dysfunction mediated by IL-1β suggests there may be an 369 oxidant stress-independent component to the endothelial dysfunction caused by IL-1β. 370
371
In addition to causing vascular dysfunction, it is known that IL-1β contributes to the development of 372 atherosclerosis, resulting from alteration of lipid metabolism and plaque development (29). Several 373
rodent and human studies demonstrate that circulating IL-1β levels are also correlated with 374 cardiovascular risk factors such as obesity, diabetes and hypertension. Notably, inflammatory 375 cytokines, such as IL-1β and IL-6, are secreted from expanding adipose tissue and are elevated in 376 obesity (47) . Functionally, IL-1β is reported to contribute to the development of type-II diabetes 377 mellitus and insulin resistance (38). An effect of inflammatory cytokines on vascular function is also 378 suggested by a human study where serum IL-1β levels were correlated with essential hypertension,although other possible risk factors of atherosclerosis could not be excluded (12). Concentrations 380 of 500 pg/ml IL-1β are also commonly seen in a systemic inflammatory response syndrome (SIRS), 381 which is associated with endothelial dysfunction in rat aorta (28). Serum levels of 30 pg/ml IL-1β 382 have also been observed in young db/db mice compared to control mice, a 3-fold increase compared 383 to control mice (32). Thus, the concentrations of IL-1β (5-500 pg/ml) used in the present study have 384 pathobiological relevance. Given the protective effects of PPARγ observed in the present study 385 against IL-1β-mediated EC dysfunction, future studies closely examining the interaction between 386 IL-1β and PPARγ on cardiovascular disease are warranted. 387 388 EC dysfunction is a marker of cardiovascular disease and is closely associated with inflammation. 389 Loss of PPARγ function in EC enhances atherosclerosis in ApoE-deficient mice fed HFD (35). This 390 study shows that PPARγ also protects against inflammatory cytokine-mediated vascular dysfunction 391 though reduction of ROS-mediated effects rather than direct antagonism of NF-κB activities. This 392 contributes to an increasing understand for the potential roles of EC-PPARγ in the pathogenesis of 393 vascular diseases. 394 genotyping mice. Transgenic mice were generated at the University of Iowa Genome Editing 399 Facility supported in part by grants from the National Institutes of Health (NIH) and from the Roy J. 400 and Lucille A. Carver College of Medicine. We would like to thank Deborah Davis and Drs. Frank M. 401 Faraci, Justin L Grobe, Jianqiang Shao, Henry L Keen at the University of Iowa for their suggestions. 402 We also acknowledge use of equipment and assistance from the Central Microscopy Facility at 403
University of Iowa. Isometric tension studies were performed using thoracic aortic rings from C57BL/6J mice treated 427 ex-vivo with or without low (1-20 pg/ml, A) or high (50-500 pg/ml, B) dose of IL-1β (1-500 pg/ml) for 428 24 hr. Concentration-dependent relaxation to ACh (1 nM-3 μM) or SNP (0.1 nM-3 μM) was 429 recorded following pre-contraction with prostaglandin F2α (PGF 2α ) (n=5-6). Aortas from NT, E-WT and E-V290M mice were pretreated with or without tempol (1 mM) for 1 hr 466 prior to high (500 pg/ml; A-B) or low (20 pg/ml; C-D) dose of IL-1β or control treatments for 24 hr. 467 Isometric tension studies were performed with ACh (1 nM-3 μM) or SNP (0.1 nM-3 μM) (n=5-6). *, 468 P<0.01 IL-1β vs. tempol+IL-1β. All data are mean±SEM. pretreated with or without apocynin (0.3 mM) for 1 hr prior to IL-1β (500 pg/ml, 24 hr) or control 473 treatments (n=6). B: Aorta from NT or E-WT were treated with IL-1β (500 pg/ml, 24 hr) alone (n=7). 
